Digital Silk Publishes New Insights into B2B Website Redesign Timelines
San Francisco B2B Brands Seek Clearer Website Redesign Timelines Amid Rising Digital Expectations
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10732/256196_b8cbca5ec485fab4_001full.jpg
According to the newly released resource, most B2B website redesign projects in San Francisco take 14 to 26 weeks, depending on project scope, stakeholder involvement, and whether new branding is needed. This transparency around timeframes comes at a crucial point, as San Francisco remains one of the most competitive B2B markets, particularly in tech and enterprise services.
A 2024 study from Forrester notes that 61% of B2B buyers now prefer digital interactions over traditional sales channels. This shift is pushing brands to invest in faster, high-performance website experiences. However, compressed expectations can often misalign with realistic delivery timelines.
"Many San Francisco businesses want a sleek, custom platform in 8 weeks, but that's not always feasible—especially when performance and conversion strategy are key," said Courtney Bozigian, VP of Digital Strategy at Digital Silk. "Outlining clear development phases can help clients balance speed, scope, and quality from day one."
Key Timelines from the San Francisco B2B Redesign Overview
Digital Silk's article highlights the following typical timelines based on San Francisco-based projects:
Discovery & Research: 2-3 weeks
Sitemap, Wireframes & UX: 3-4 weeks
UI Design: 4-5 weeks
Development: 6-8 weeks
QA, Optimisation & Launch: 1-3 weeks
This timeline expands when content creation, multilingual development, or a complete rebrand is included.
Growing Demand for Strategic Website Redesigns
Increased digital demand and the rise of AI-enhanced platforms are also influencing timeline expectations. Many San Francisco enterprises are incorporating long-term scalability and integration with CRMs, analytics, and marketing automation systems into their web builds.
The full article can be read here:
About Digital Silk
Digital Silk is an award-winning San Francisco Web Design Agency focused on growing brands online. With a team of seasoned experts, Digital Silk delivers industry-leading digital experiences through strategic branding and cutting-edge web design to drive more conversions and digital marketing services to boost awareness and engagement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
How Steve Witkoff became Trump's best friend
When it comes to Donald Trump's plan to end conflicts around the world, one name keeps coming up: Steve Witkoff. For The National, CBC's Eli Glasner breaks down how the former real estate developer with no diplomatic experience earned the U.S. president's trust and a key role negotiating peace.
Globe and Mail
2 hours ago
- Globe and Mail
Profound Medical Posts Wider Loss in Q2
Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
Braze (BRZE): A Promising Player in Marketing Tech or Just Another Risky Bet?
Explore the exciting world of Braze (NASDAQ: BRZE) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 16, 2025. The video was published on Aug. 14, 2025. Should you invest $1,000 in Braze right now? Before you buy stock in Braze, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Braze wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
